Results 121 to 130 of about 2,329 (147)

Sphingosine-1-Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety. [PDF]

United European Gastroenterol J
Fantini MC, Centonze D, Giacobazzi G, Benemei S, Romeo E.   +4 more
europepmc   +1 more source

Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative. [PDF]

Clin Pharmacol Ther
Weissfeld JL, Iyer GS, Seo SC, Giffin A, Simon AL, Kluberg SA, Hoffman ER, Jones JT, Dutcher SK, Korvick JA.   +9 more
europepmc   +1 more source

IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management? [PDF]

J Clin Med
Alsaeid M, Abu Hawi O, Bessissow T, Lakatos PL.   +3 more
europepmc   +1 more source

The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis. [PDF]

J Clin Med
Choon XY, Yeo JH, White C, Sharma E, Samaan MA.   +4 more
europepmc   +1 more source

CU104, a novel barrier function enhancer, improves colitis via modulation of barrier function and immune cell recruitment. [PDF]

Front Immunol
Park IS, Kim JH, Kim D, Kim YW, Shin Y, Kim KB, Zhang H, Kim TI, Kim SW, Kwon YG, Cheon JH.   +10 more
europepmc   +1 more source

Glial Fibrillary Acidic Protein as a Marker of Disease in Relapsing Multiple Sclerosis: Post Hoc Analysis of Phase 3 Ozanimod Trials. [PDF]

Eur J Neurol
Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Maddux R, Southworth H, Kappos L, Cohen JA.   +9 more
europepmc   +1 more source

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry. [PDF]

J Neurol
Guger M, Enzinger C, Heschl B, Di Pauli F, Gradl C, Kalcher S, Kvas E, Berger T, Austrian MS Treatment Registry (AMSTR).   +8 more
europepmc   +1 more source